https://ap24534inhibitor.com/s....ite-variety-with-the
A retrospective, multicenter, nationwide cohort study sought to determine the impact of the monoclonal antibody regdanvimab, which is directed against SARS-CoV-2. Regdanvimab was a prescribed treatment in South Korea, both preceding and following the advent of the delta variant, deployed against its threat. The performance of regdanvimab, although diminished, was still present and measurable. From December 2020 through September 2021, patients with mild to moderate COVI
Like
Comment
Share
